Products
Clervonafusp Alfa Biosimilar Fusion Protein (SLC29A2/ENT2) for Research
Pre-Made Clervonafusp Alfa Biosimilar, Fusion Protein targeting SLC29A2/ENT2 fused with human GAA (glucosidase alpha, acid, lysosomal alpha-glucosidase )(Pr67-952) (1:2) Enzyme substitute: Recombinant therapeutic protein targeting DER12/HNP36 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Clervonafusp Alfa is consisting of immunoglobulin G1-kappa, cell-penetrating humanized Fab fragment targeting the equilibrative nucleoside transporter 2 (ENT2), fused with a human lysosomal α-glucosidase fragment, glycoform alfa. It is used to treat Pompe disease.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-783-1mg | 1mg | 3090 |
| GMP-Bios-INN-783-10mg | 10mg | |
| GMP-Bios-INN-783-100mg | 100mg | |
| GMP-Bios-INN-783-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Clervonafusp Alfa Biosimilar, Fusion Protein targeting SLC29A2/ENT2 fused with human GAA (glucosidase alpha, acid, lysosomal alpha-glucosidase )(Pr67-952) (1:2) Enzyme substitute: Recombinant therapeutic protein targeting DER12/HNP36 |
| INN Name | Clervonafusp Alfa |
| Target | SLC29A2 |
| Format | Fusion Protein |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | F(ab')2 - G1 - kappa |
| VD LC | F(ab')2 - G1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Valerion Therapeutics, LLC. (Concord MA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - SLC29A2
1. Protein Equilibrative nucleoside transporter 2
2. Gene SLC29A2
3. Organism Homo sapiens (Human)
Function
Mediates equilibrative transport of purine, pyrimidine nucleosides and the purine base hypoxanthine. Very less sensitive than SLC29A1 to inhibition by nitrobenzylthioinosine (NBMPR), dipyridamole, dilazep and draflazine.
Kinetics
Vmax for adenosine uptake is about the same for SLC29A1 and SLC29A2.
KM=0.2 mM for uridine
KM=0.75 mM for adenosinebr>
